Journal
MYCOSES
Volume 63, Issue 10, Pages 1047-1059Publisher
WILEY
DOI: 10.1111/myc.13157
Keywords
antifungal agents; blood-brain barrier; central nervous system; invasive fungal infections; pharmacokinetic
Categories
Funding
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [405556/2018-7]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2017/19374-9]
Ask authors/readers for more resources
Invasive fungal infections (IFIs) in the central nervous system (CNS) are particularly hard to treat and are associated with high morbidity and mortality rates. Four chemical classes of systemic antifungal agents are used for the treatment of IFIs (eg meningitis), including polyenes, triazoles, pyrimidine analogues and echinocandins. This review will address all of these classes and discuss their penetration and accumulation in the CNS. Treatment of fungal meningitis is based on the antifungal that shows good penetration and accumulation in the CNS. Pharmacokinetic data concerning the entry of antifungal agents into the intracranial compartments are faulty. This review will provide an overview of the ability of systemic antifungals to penetrate the CNS, based on previously published drug physicochemical properties and pharmacokinetic data, for evaluation of the most promising antifungal drugs for the treatment of fungal CNS infections. The studies selected and discussed in this review are from 1990 to 2019.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available